'Disease-Reversing' Biotech Startup Altos Launches With $3B War Chest In 3 Cities
Altos Labs, a life sciences startup with a mission to “reverse disease, injury, and the disabilities that can occur throughout life,” officially launched this week, boasting an international roster of top scientists and announcing $3B in funding, raised in part from big-name early funders who include Israeli-Russian tech investor Yuri Milner. Jeff Bezos has long been rumored to be a significant early investor.
The firm has recruited an impressive list of talent, including former National Cancer Institute head Rick Klausner as chief scientist and Hal Barron, GlaxoSmithKline's research and development chief, as CEO. The announcement listed San Diego, San Francisco and Cambridge, UK, as the locations of its labs and operations.
A spokesperson declined to offer Bisnow any additional details about the firm’s facilities and real estate portfolio, but in September, it was revealed that the company leased nearly 250K SF across six buildings in Redwood Life, a business park acquired by Longfellow Real Estate Partners and PGIM in 2019.
The firm is the latest to focus on ostensibly anti-aging technology and has attracted significant interest from Silicon Valley, as well as a team of scientists and Nobel laureates working at the firm’s Institutes of Science and Medicine. It is the largest and latest in a recent string of cellular rejuvenation companies receiving significant investment.
